RFA
ABCL icon

Reilly Financial Advisors’s AbCellera Biologics ABCL Stock Holding History

Reilly Financial Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$1K Buy
+100
New +$1.52K ﹤0.01% 1033

Other funds holding ABCL

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
DB
DCVC Bio Palo Alto, California $313K AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Reilly Financial Advisors's ABCL Position: Q4 2021 in Review

Reilly Financial Advisors opened a new position in AbCellera Biologics (ABCL) in Q4 2021: 100 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #1033 among its holdings.

124 funds tracked by Wall St. Rank hold ABCL as of Q4 2021.

  • Reilly Financial Advisors held 100 shares of AbCellera Biologics worth $1K as of Q4 2021.
  • AbCellera Biologics was a new Reilly Financial Advisors position in Q4 2021.
  • AbCellera Biologics made up ﹤0.01% of Reilly Financial Advisors's portfolio in Q4 2021, its #1033 holding.
  • 124 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2021.

Based on Reilly Financial Advisors's 13F filing for Q4 2021, filed 25 Jan 2022.